Financial PerformanceAt the end of 2Q24, scPharma’s cash position was $38.5M, not inclusive of recent financings, with OpEx slightly up Q/Q at $22.5M.
Operational IssuesThe Change Healthcare cyberattacks had a ~10% impact on prescriptions filled in the quarter, translating to lost sales of $600K-$700K.
Product LaunchSCPH stock has been under pressure as investors wait for signs of a more tangible launch inflection for Furoscix in decompensated heart failure (HF).